Replies to post #350 on Rich Pharmaceuticals Inc. (fka RCHA)

[was GoldenDD]

thinking whether I should sell or not, current market cap around 1 mill , this could be potential be worth 100 mill $,,so hmmmm thinking

[MR.METICULOUS]

we have a multi-penny 3 day+ runner here....I grad I bought in, if only with 1 million shares!!!

BOOOOOM!!!!

[Helter Skelter]

Chang has had a year and a half to lower the AS...

On September 5, 2013, the Company increased the authorized common shares, par value $0.001, from 90,000,000 shares to 37,503,000,000 shares.

...from 37.5 billion shares...to something "more perceptible"...

rcha pps was OOO8 just the other day. Conversions go off @ a 45% discount.

55% of OOO8 = OOO44 (trips).

$208,395 / OOO44 = 947,250,000 shares.

Almost one billion shares.

Only 137 million traded so far today...

On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued on this note for the period ended September 30, 2014 is $84.

As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the three months ending September 30, 2014: $37,500 note dated March 11, 2014 ($25,500 balance at September 30, 2014); $64,500 note dated September 18, 2014; $60,500 note dated August 13, 2014; $57,895 note dated August 19, 2014.

These highlighted convertible notes total $208,395. Just using this number creates dilution of nearly one billion shares dependent on the notes' respective terms...

[stervc]

Key RCHA & WX:NYSE Relationship…

Within the recent news below, RCHA indicates that they have a key relationship with Wuxi Apptec Biopharmaceutical (WX) which trades on the NYSE that is trading at over $40.00+ per share:

http://finance.yahoo.com/news/rich-pharmaceuticals-announces-completion-manufacture-144500701.html
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China. This new batch of RP-323 represents a new second-generation compound with improved product usability and stability. Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323. Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.

WX:NYSE is where RCHA had competed its GMP clinical batch of RP-323 study drug that was manufactured at the WX:NYSE state-of-the-art facility. RCHA is the company that developed the new formulation and all regulatory required testing methods in 2014, but RCHA transferred the proprietary technology ”successfully” to WX:NYSE for the GMP production of RP-323. This is huge.

Also, WX:NYSE is expected to generated approximately $674 Million in Revenues and to deliver profitability in the area of $1.56 to $1.87 EPS (Earnings Per Share) I bring this point up because I am confident that the due diligence for a company of this magnitude believe this much in RCHA, then I must humble myself and any DD that I think is worthy of passing any kind of negative judgment on this company’s future.

http://ir.wuxiapptec.com/phoenix.zhtml?c=212698&p=irol-IRHome

http://ir.wuxiapptec.com/phoenix.zhtml?c=212698&p=irol-newsArticle&ID=2005433
HANGHAI , Jan. 9, 2015 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, today announced that it has updated its 2014 financial guidance. The company expects to achieve total revenues for full-year 2014 of approximately $674 million, compared to previous guidance of $670-672 million. The company expects to achieve diluted EPS of approximately $1.87 (non-GAAP) and approximately $1.56 (GAAP), compared to previous guidance of 1.83-1.86 (non-GAAP) and $1.55-1.58 (GAAP).

v/r
Sterling

[king koopa]

it is quite the honor to be on this board with you and your unmatched DD.

Your DD helps explain why when I was buying at first, my first bid was .0013, my bid would be visible and first in line to get filled, and millions would go through but not fill my bid. This happened multiple times. Granted I ended up getting 2.1 million shares after it dropped some more, there was some very sketchy selling going on, and it was always very challenging to get shares on the bid. Usually a sign that someone else knows something and was supposed to be getting their shares first :)